Key facts
- This page summarizes Jiming Zhou's Form 4 filing for 20/20 Biolabs, Inc. (AIDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Apr 2026, 17:56.
Jiming Zhou - 02 Apr 2026 Form 4 Insider Report for 20/20 Biolabs, Inc. (AIDX)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- AIDX
- Reported as of
- 02 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Apr 2026, 17:56:27 UTC
- Prior SEC filing
- 17 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jiming Zhou
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jiming Zhou filed Form 4 for 20/20 Biolabs, Inc. (AIDX) on 06 Apr 2026.
Change
- Previous filing in this sequence was filed on 17 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002109760
Primary reporting owner
Zhou Jiming
- Relationship
- Chief Operating Officer
- Address
- C/O 20/20 BIOLABS, INC.,, 5810 GAITHER ROAD, SUITE 235, GAITHERSBURG
- Signature
- /s/ Jiming Zhou
- Signature date
- 06 Apr 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AIDX
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +150,000
- Change %
- Price
- $0.000000*
- Shares after
- 150,000
- Date
- 02 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $1.88
* marks a reported price that did not pass the local price check.